Sfoglia per Autore
Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia
2020-01-01 Griggio V, Perutelli F, Salvetti C, Boccellato E, Boccadoro M, Vitale C, Coscia M
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia
2020-01-01 Griggio, Valentina; Vitale, Candida; Todaro, Maria; Riganti, Chiara; Kopecka, Joanna; Salvetti, Chiara; Bomben, Riccardo; Dal Bo, Michele; Magliulo, Daniela; Rossi, Davide; Pozzato, Gabriele; Bonello, Lisa; Marchetti, Monia; Omedè, Paola; Kodipad, Ahad Ahmed; Laurenti, Luca; Del Poeta, Giovanni; Mauro, Francesca Romana; Bernardi, Rosa; Zenz, Thorsten; Gattei, Valter; Gaidano, Gianluca; Foà, Robin; Massaia, Massimo; Boccadoro, Mario; Coscia, Marta
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation
2020-01-01 Apolito V.; Giaccone L.; Ferrero S.; Larocca A.; Cavallo F.; Coscia M.; Beggiato E.; Butera S.; Martella F.; Dainese C.; Cetani G.; Scaldaferri M.; Cattel F.; Boccadoro M.; Ferrero D.; Bruno B.; Cerrano M.
Should high-risk smouldering multiple myeloma be treated?
2020-01-01 Richard S.; Jagannath S.; Boccadoro M.; Mina R.
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
2020-01-01 Terpos E.; Engelhardt M.; Cook G.; Gay F.; Mateos M.-V.; Ntanasis-Stathopoulos I.; van de Donk N.W.C.J.; Avet-Loiseau H.; Hajek R.; Vangsted A.J.; Ludwig H.; Zweegman S.; Moreau P.; Einsele H.; Boccadoro M.; San Miguel J.; Dimopoulos M.A.; Sonneveld P.
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study
2020-01-01 Mina R.; Belotti A.; Petrucci M.T.; Zambello R.; Capra A.; Di Lullo G.; Ronconi S.; Pescosta N.; Grasso M.; Monaco F.; Cellini C.; Gobbi M.; Ballanti S.; de Fabritiis P.; Mosca-Siez M.L.; Marchetti M.; Liberati A.M.; Offidani M.; Giuliani N.; Ria R.; Musto P.; Romano A.; Sonneveld P.; Boccadoro M.; Larocca A.
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents
2020-01-01 Mina R.; Joseph N.S.; Gay F.; Kastritis E.; Petrucci M.T.; Kaufman J.L.; Montefusco V.; Gavriatopoulou M.; Patriarca F.; Omede P.; Boise L.H.; Roussou M.; Giuliani N.; Oliva S.; Offidani M.; Belotti A.; Jaye D.L.; De Paoli L.; Terpos E.; Lonial S.; Boccadoro M.; Nooka A.K.; Dimopoulos M.A.
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
2020-01-01 Larocca, Alessandra; Mina, Roberto; Offidani, Massimo; Liberati, Anna Marina; Ledda, Antonio; Patriarca, Francesca; Evangelista, Andrea; Spada, Stefano; Benevolo, Giulia; Oddolo, Daniela; Innao, Vanessa; Cangialosi, Clotilde; Bernardini, Annalisa; Musto, Pellegrino; Amico, Valeria; Fraticelli, Vincenzo; Paris, Laura; Giuliani, Nicola; Falcone, Antonietta Pia; Zambello, Renato; De Paoli, Lorenzo; Romano, Alessandra; Palumbo, Antonio; Montefusco, Vittorio; Hajek, Roman; Boccadoro, Mario; Bringhen, Sara
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing
2020-01-01 D'Agostino, Mattia; Zaccaria, Gian Maria; Ziccheddu, Bachisio; Rustad, Even H; Genuardi, Elisa; Capra, Andrea; Oliva, Stefania; Auclair, Daniel; Yesil, Jennifer; Colucci, Paola; Keats, Jonathan J; Gambella, Manuela; Bringhen, Sara; Larocca, Alessandra; Boccadoro, Mario; Bolli, Niccolò; Maura, Francesco; Gay, Francesca
Gammopatie monoclonali
2020-01-01 Chiara Cerrato, Roberto Mina, Mario Boccadoro
Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia
2020-01-01 Cerrano M.; Castella B.; Lia G.; Olivi M.; Faraci D.G.; Butera S.; Martella F.; Scaldaferri M.; Cattel F.; Boccadoro M.; Massaia M.; Ferrero D.; Bruno B.; Giaccone L.
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
2020-01-01 Oliva S.; D'Agostino M.; Boccadoro M.; Larocca A.
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells
2020-01-01 Vitale C, Todaro M, Griggio V, Salvetti C, Riganti C, Landesman Y, Boccadoro M, Coscia M.
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs
2020-01-01 Vitale C.; Montalbano M.C.; Salvetti C.; Boccellato E.; Griggio V.; Boccadoro M.; Coscia M.
Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
2020-01-01 Mina, Roberto; Oliva, Stefania; Boccadoro, Mario
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
2020-01-01 Cavo M.; Gay F.; Beksac M.; Pantani L.; Petrucci M.T.; Dimopoulos M.A.; Dozza L.; van der Holt B.; Zweegman S.; Oliva S.; van der Velden V.H.J.; Zamagni E.; Palumbo G.A.; Patriarca F.; Montefusco V.; Galli M.; Maisnar V.; Gamberi B.; Hansson M.; Belotti A.; Pour L.; Ypma P.; Grasso M.; Croockewit A.; Ballanti S.; Offidani M.; Vincelli I.D.; Zambello R.; Liberati A.M.; Andersen N.F.; Broijl A.; Troia R.; Pascarella A.; Benevolo G.; Levin M.-D.; Bos G.; Ludwig H.; Aquino S.; Morelli A.M.; Wu K.L.; Boersma R.; Hajek R.; Durian M.; von dem Borne P.A.; Caravita di Toritto T.; Zander T.; Specchia G.; Waage A.; Gimsing P.; Mellqvist U.-H.; van Marwijk Kooy M.; Minnema M.; Mandigers C.; Cafro A.M.; Palmas A.; Carvalho S.; Spencer A.; Boccadoro M.; Sonneveld P.
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
2020-01-01 Montefusco V.; Gay F.; Spada S.; de Paoli L.; Raimondo F.D.; Ribolla R.; Musolino C.; Patriarca F.; Musto P.; Galieni P.; Ballanti S.; Nozzoli C.; Cascavilla N.; Ben-Yehuda D.; Nagler A.; Hajek R.; Offidani M.; Liberati A.M.; Sonneveld P.; Cavo M.; Corradini P.; Boccadoro M.
Monoclonal antibodies to treat multiple myeloma: A dream come true
2020-01-01 D'Agostino M.; Innorcia S.; Boccadoro M.; Bringhen S.
Anticorpi monoclonali bispecifici nel trattamento del mieloma multiplo
2019-01-01 Mattia D'Agostino; Mario Boccadoro
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study
2019-01-01 Plesner T.; Arkenau H.-T.; Gay F.; Minnema M.C.; Boccadoro M.; Moreau P.; Cavenagh J.; Perrot A.; Laubach J.P.; Krejcik J.; Ahmadi T.; de Boer C.; Chen D.; Chiu C.; Schecter J.M.; Richardson P.G.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia | 2020 | Griggio V, Perutelli F, Salvetti C, Boccellato E, Boccadoro M, Vitale C, Coscia M | |
| HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia | 2020 | Griggio, Valentina; Vitale, Candida; Todaro, Maria; Riganti, Chiara; Kopecka, Joanna; Salvetti, Chiara; Bomben, Riccardo; Dal Bo, Michele; Magliulo, Daniela; Rossi, Davide; Pozzato, Gabriele; Bonello, Lisa; Marchetti, Monia; Omedè, Paola; Kodipad, Ahad Ahmed; Laurenti, Luca; Del Poeta, Giovanni; Mauro, Francesca Romana; Bernardi, Rosa; Zenz, Thorsten; Gattei, Valter; Gaidano, Gianluca; Foà, Robin; Massaia, Massimo; Boccadoro, Mario; Coscia, Marta | |
| Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation | 2020 | Apolito V.; Giaccone L.; Ferrero S.; Larocca A.; Cavallo F.; Coscia M.; Beggiato E.; Butera S.; Martella F.; Dainese C.; Cetani G.; Scaldaferri M.; Cattel F.; Boccadoro M.; Ferrero D.; Bruno B.; Cerrano M. | |
| Should high-risk smouldering multiple myeloma be treated? | 2020 | Richard S.; Jagannath S.; Boccadoro M.; Mina R. | |
| Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) | 2020 | Terpos E.; Engelhardt M.; Cook G.; Gay F.; Mateos M.-V.; Ntanasis-Stathopoulos I.; van de Donk N.W.C.J.; Avet-Loiseau H.; Hajek R.; Vangsted A.J.; Ludwig H.; Zweegman S.; Moreau P.; Einsele H.; Boccadoro M.; San Miguel J.; Dimopoulos M.A.; Sonneveld P. | |
| Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study | 2020 | Mina R.; Belotti A.; Petrucci M.T.; Zambello R.; Capra A.; Di Lullo G.; Ronconi S.; Pescosta N.; Grasso M.; Monaco F.; Cellini C.; Gobbi M.; Ballanti S.; de Fabritiis P.; Mosca-Siez M.L.; Marchetti M.; Liberati A.M.; Offidani M.; Giuliani N.; Ria R.; Musto P.; Romano A.; Sonneveld P.; Boccadoro M.; Larocca A. | |
| Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents | 2020 | Mina R.; Joseph N.S.; Gay F.; Kastritis E.; Petrucci M.T.; Kaufman J.L.; Montefusco V.; Gavriatopoulou M.; Patriarca F.; Omede P.; Boise L.H.; Roussou M.; Giuliani N.; Oliva S.; Offidani M.; Belotti A.; Jaye D.L.; De Paoli L.; Terpos E.; Lonial S.; Boccadoro M.; Nooka A.K.; Dimopoulos M.A. | |
| First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials | 2020 | Larocca, Alessandra; Mina, Roberto; Offidani, Massimo; Liberati, Anna Marina; Ledda, Antonio; Patriarca, Francesca; Evangelista, Andrea; Spada, Stefano; Benevolo, Giulia; Oddolo, Daniela; Innao, Vanessa; Cangialosi, Clotilde; Bernardini, Annalisa; Musto, Pellegrino; Amico, Valeria; Fraticelli, Vincenzo; Paris, Laura; Giuliani, Nicola; Falcone, Antonietta Pia; Zambello, Renato; De Paoli, Lorenzo; Romano, Alessandra; Palumbo, Antonio; Montefusco, Vittorio; Hajek, Roman; Boccadoro, Mario; Bringhen, Sara | |
| Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing | 2020 | D'Agostino, Mattia; Zaccaria, Gian Maria; Ziccheddu, Bachisio; Rustad, Even H; Genuardi, Elisa; Capra, Andrea; Oliva, Stefania; Auclair, Daniel; Yesil, Jennifer; Colucci, Paola; Keats, Jonathan J; Gambella, Manuela; Bringhen, Sara; Larocca, Alessandra; Boccadoro, Mario; Bolli, Niccolò; Maura, Francesco; Gay, Francesca | |
| Gammopatie monoclonali | 2020 | Chiara Cerrato, Roberto Mina, Mario Boccadoro | |
| Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia | 2020 | Cerrano M.; Castella B.; Lia G.; Olivi M.; Faraci D.G.; Butera S.; Martella F.; Scaldaferri M.; Cattel F.; Boccadoro M.; Massaia M.; Ferrero D.; Bruno B.; Giaccone L. | |
| Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma | 2020 | Oliva S.; D'Agostino M.; Boccadoro M.; Larocca A. | |
| Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells | 2020 | Vitale C, Todaro M, Griggio V, Salvetti C, Riganti C, Landesman Y, Boccadoro M, Coscia M. | |
| Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs | 2020 | Vitale C.; Montalbano M.C.; Salvetti C.; Boccellato E.; Griggio V.; Boccadoro M.; Coscia M. | |
| Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives | 2020 | Mina, Roberto; Oliva, Stefania; Boccadoro, Mario | |
| Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study | 2020 | Cavo M.; Gay F.; Beksac M.; Pantani L.; Petrucci M.T.; Dimopoulos M.A.; Dozza L.; van der Holt B.; Zweegman S.; Oliva S.; van der Velden V.H.J.; Zamagni E.; Palumbo G.A.; Patriarca F.; Montefusco V.; Galli M.; Maisnar V.; Gamberi B.; Hansson M.; Belotti A.; Pour L.; Ypma P.; Grasso M.; Croockewit A.; Ballanti S.; Offidani M.; Vincelli I.D.; Zambello R.; Liberati A.M.; Andersen N.F.; Broijl A.; Troia R.; Pascarella A.; Benevolo G.; Levin M.-D.; Bos G.; Ludwig H.; Aquino S.; Morelli A.M.; Wu K.L.; Boersma R.; Hajek R.; Durian M.; von dem Borne P.A.; Caravita di Toritto T.; Zander T.; Specchia G.; Waage A.; Gimsing P.; Mellqvist U.-H.; van Marwijk Kooy M.; Minnema M.; Mandigers C.; Cafro A.M.; Palmas A.; Carvalho S.; Spencer A.; Boccadoro M.; Sonneveld P. | |
| Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs | 2020 | Montefusco V.; Gay F.; Spada S.; de Paoli L.; Raimondo F.D.; Ribolla R.; Musolino C.; Patriarca F.; Musto P.; Galieni P.; Ballanti S.; Nozzoli C.; Cascavilla N.; Ben-Yehuda D.; Nagler A.; Hajek R.; Offidani M.; Liberati A.M.; Sonneveld P.; Cavo M.; Corradini P.; Boccadoro M. | |
| Monoclonal antibodies to treat multiple myeloma: A dream come true | 2020 | D'Agostino M.; Innorcia S.; Boccadoro M.; Bringhen S. | |
| Anticorpi monoclonali bispecifici nel trattamento del mieloma multiplo | 2019 | Mattia D'Agostino; Mario Boccadoro | |
| Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study | 2019 | Plesner T.; Arkenau H.-T.; Gay F.; Minnema M.C.; Boccadoro M.; Moreau P.; Cavenagh J.; Perrot A.; Laubach J.P.; Krejcik J.; Ahmadi T.; de Boer C.; Chen D.; Chiu C.; Schecter J.M.; Richardson P.G. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile